Back

Cardiovascular and survival outcomes associated with spironolactone use in dialysis-dependent heart failure

9 May 2026 (08:30 - 09:15)
Organised by: Logo
Congress Presentation Part of: Renal function and fluid management in heart failure patients Pharmacotherapy HFA Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Bu Yuan Hsiao

Taipei Medical University Hospital, Taipei (Taiwan)

5 More presentations in this session

Presentation thumbnail
The presence and prognostic effect of albuminuria in light of the rapid-up titration programme of guideline-directed medical therapy in heart failure
Doctor P. Schaffer (Budapest, HU)
Abstract Slides Video
Presentation thumbnail
Optimising heart failure treatment in patients receiving renal replacement therapy: the role of a cardiorenal unit
Doctor E. Fuente Gonzalez (Las Palmas de Gran Canaria, ES)
Abstract Slides Video
Presentation thumbnail
Type 2 diabetes and chronic kidney disease combinations in heart failure across the ejection fraction spectrum: clinical associations, medication use, and cause-specific outcomes
Professor L. Lund (Stockholm, SE)
Abstract Slides Video
Presentation thumbnail
Weight loss and clinical decongestion across heart failure phenotypes: a post-hoc analysis of a multicentre randomised trial (duel-hf)
Doctor Y. Mareev (Glasgow, GB)
Abstract Slides Video
Presentation thumbnail
Renal function at discharge matters: graded prognostic impact of kidney dysfunction after decompensated heart failure with reduced ejection fraction
Mrs S. Valdivielso (Barcelona, ES)
Abstract Slides Video

Access the full session

Session thumbnail
Renal function and fluid management in heart failure patients

The Event

Event poster

Heart Failure 2026

9 May 2026 08:30 CET
You may be interested in
thumbnail
Congress Session
Cardiorenal interactions and early therapeutic signals in acute heart failure
thumbnail
Congress Session
New tools to detect and treat acute heart failure
thumbnail
Congress Presentation
Initiation of mineralocorticoid receptor antagonists in patients with cardiorenal diseases: potassium changes, hyperkalaemia risk and discontinuation in the CaRe study

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources